Barry Make, MD
Professor of Medicine
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado School of Medicine
Director, Emphysema Center, Pulmonary Rehabilitation, and Respiratory Care
National Jewish Medical and Research Center
Douglas Mapel, MD, MPH
Lovelace Clinic Foundation
CME and CPE, 1 hour; Nursing and NP CE, 1.2 hours
Despite its prevalence and associated morbidity, COPD may manifest in strikingly different ways in a population of patients. Some patients with significant airflow limitation may be asymptomatic, while others with milder disease may be more significantly impaired. The management of COPD and its periodic exacerbations needs to be tailored to the individual patient in terms of pharmacologic and nonpharmacologic therapies.
A variety of medications exists that can provide relief to patients with COPD and greatly increase their quality of life and daily functioning. The medications chosen and dosing regimen should be tailored to the individual patient, and changed as needed to reflect improving or worsening symptoms.
While COPD has no cure, its progression can be slowed and its symptoms managed through aggressive treatment that requires a partnership between the health care practitioner and the patient.
This program will focus on the goals of COPD management and the variety of pharmacotherapeutic options available for its management. Updated recommendations reflecting the newly-revised GOLD Guidelines will be included, as will extensive discussion of COPD pharmacotherapeutic mainstays such as bronchodilators. Further, new therapies presently under investigation for the management of COPD will be discussed.
. Target Audience
Physicians, nurses, nurse practitioners, and pharmacists with an interest in COPD.
Upon completion of this educational activity, the participant should be able to:
Review the goals for the management of COPD and its exacerbations.
Describe the role of bronchodilators in the management of COPD.
Know when to institute a trial of inhaled corticosteroids in COPD.
Discuss potential new therapies for the management of COPD.
Douglas Mapel, MD, MPH discloses that he has received research grants from GlaxoSmithKline, Pfizer Inc, and Pharmacia & Upjohn, Inc. He will also be discussing off-label, unapproved and/or investigational uses of medications in this program.
Barry Make, MD discloses that he has received research grants or support from Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Sepracor, Inc. He has also received consulting fees from and is on the Speaker’s Bureau for Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline and Novartis Pharmaceuticals Corporation. He will also be discussing off-label, unapproved and/or investigational uses of medications in this program.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Consultant and Medical Communications Media, Incorporated. AKH Consultant is accredited by the ACCME to provide continuing medical education for physicians.
AKH Consultant designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.
The release date of this activity is February, 2004. Credit expires December 31, 2005.
This program has been approved for 1.2 hours of continuing nursing education by AKH Consultant. AKH Consultant is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation, and is an approved provider through the Boards of Nursing in CA, #CEP12070 & IA, #277. Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Nurse Practitioner CE
This program has been approved for 1.2 hours of continuing education for nurse practitioners by AKH Consultant. AKH Inc. is approved as a provider of nursing and nurse practitioner continuing education by the American Academy of Nurse Practitioners. #030803.
This program (UPN 077-999-04-004-H01) was developed by AKH Consultant and is approved for 1.0 Contact Hour (0.1 CEU). AKH Consultant is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Credit expiration date is December 31, 2005. A Statement of Credit will be awarded upon submission of the post-test with a minimum score of 70%.
AAPA accepts Category I CME credit for the PRA from organizations accredited by ACCME. All programs on cmecorner.com which carry ACCME Category I CME credit are acceptable towards the PA Category I (Preapproved) CME requirement.
PAs requesting credit should check the “Physician” box on the post-test.
Commercial Support Statements
This program has been made possible by an unrestricted educational grant from GlaxoSmithKline.
Click on the "Start program" icon.
The next screen will permit you to check for or download the Flash player required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME or CE certificate.
The information contained in this program does not necessarily reflect the opinions or recommendations of GlaxoSmithKline, AKH Consultant, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.